HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)
Sponsor: Baylor College of Medicine
This PHASE1 trial investigates Ewing Sarcoma and HER-2 Protein Overexpression and is currently actively recruiting participants. Baylor College of Medicine leads this study, which shows 14 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Dec 2024 — Dec 2025 [monthly]
Recruiting PHASE1
-
Oct 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
▶ Show 9 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Jul 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Mar 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE1
-
Jan 2022 — Jan 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- National Cancer Institute (NCI)
- St. Baldrick's Foundation
- Stand Up To Cancer
- The Faris Foundation USA
- Triumph Over Kid Cancer Foundation
For direct contact, visit the study record on ClinicalTrials.gov .